Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH.[A242287]
Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with [finasteride] for the treatment of benign prostatic hypertrophy (BPH).[L39095,L39439] It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with [macitentan] or other endothelin-1 antagonists.[L39100,L39105]
Categories
5-alpha Reductase InhibitorsAntihypertensive AgentsAntihypertensives for Pulmonary Arterial HypertensionCarbolinesCardiovascular AgentsCytochrome P-450 CYP3A SubstratesCytochrome P-450 CYP3A4 SubstratesCytochrome P-450 CYP3A5 SubstratesCytochrome P-450 SubstratesDrugs that are Mainly Renally ExcretedDrugs Used in Benign Prostatic HypertrophyDrugs Used in Erectile DysfunctionEnzyme InhibitorsGenito Urinary System and Sex HormonesGenitourinary AgentsHeterocyclic Compounds, Fused-RingIndole AlkaloidsIndolesPhosphodiesterase 5 InhibitorsPhosphodiesterase InhibitorsPyridinesUrological AgentsUrologicalsVasodilating Agents
ATC-Code
G04BE08C02KX52G04CB51G04CA54C02KX54
CAS number
171596-29-5
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682